📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. (2016)

First Author: Fitzgerald N

Attributed to: The UK Centre for Tobacco Control Studies funded by ESRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/add.13438

PubMed Identifier: 27262594

Publication URI: http://europepmc.org/abstract/MED/27262594

Type: Journal Article/Review

Volume: 111

Parent Publication: Addiction (Abingdon, England)

Issue: 8

ISSN: 0965-2140